Video Experimental Relacionado
Updated: May 5, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.7K
Riesgo de diabetes incidente con dosis intensivas en comparación con la terapia con estatinas de dosis moderada: un
David Preiss1, Sreenivasa Rao Kondapally Seshasai, Paul Welsh
1BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Pl, Glasgow G12 8TA, Scotland, United Kingdom. david.preiss@glasgow.ac.uk
JAMA
|June 23, 2011
Resumen
La terapia con dosis intensivas de estatinas aumenta el riesgo de desarrollar diabetes mellitus de nueva aparición en un 12% en comparación con la terapia con dosis moderadas. Sin embargo, también reduce los eventos cardiovasculares en un 16%.
Área de la Ciencia:
- Cardiología Cardiología.
- Trastornos metabólicos Los trastornos metabólicos son trastornos metabólicos que se producen en el cuerpo.
- Los ensayos clínicos son ensayos clínicos.
Sus antecedentes:
- La terapia con estatinas está relacionada con un mayor riesgo de diabetes mellitus.
- Metaanálisis anteriores indican una posible asociación entre las estatinas y el desarrollo de diabetes.
Objetivo del estudio:
- Para comparar el riesgo de diabetes de nueva aparición entre la terapia de dosis intensiva y la dosis moderada de estatinas.
- Para evaluar los beneficios cardiovasculares de la terapia con estatinas en dosis intensivas frente a la terapia con dosis moderadas.
Principales métodos:
- Se realizó un metanálisis de 5 ensayos controlados aleatorios.
- Los ensayos incluidos compararon la terapia de dosis intensiva frente a la dosis moderada de estatinas en más de 1000 participantes seguidos durante más de 1 año.
- Se extrajeron y analizaron datos sobre diabetes de nueva aparición y eventos cardiovasculares importantes utilizando modelos de efectos aleatorios.
Principales resultados:
- La terapia con dosis intensivas de estatinas se asoció con un aumento del 12% en el riesgo de diabetes de nueva aparición (OR 1,12; IC del 95%, 1,04-1,22).
- El número necesario para dañar la diabetes de nueva aparición fue de 498 por año.
- La terapia con dosis intensivas de estatinas mostró una reducción del 16% en los eventos cardiovasculares mayores (OR 0,84; IC del 95%, 0,75-0,94).
- El número necesario para tratar eventos cardiovasculares fue de 155 por año.
Conclusiones:
- La terapia con dosis intensivas de estatinas se asocia con un mayor riesgo de diabetes de nueva aparición en comparación con la terapia con dosis moderadas.
- A pesar del aumento del riesgo de diabetes, las estatinas de dosis intensivas proporcionan beneficios cardiovasculares significativos.
Videos de Conceptos Relacionados
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:21Drug Dosing: Obese Patients
368
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
368
01:16Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
993
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
01:24Type II Diabetes II: Pathophysiology
28
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
28